InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated ...

InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient de ...
pv magazine USA

Researchers build 22.36%-efficient 3D/2D solar modules based on stabilized hybrid perovskite

An international research team has developed perovskite solar cells and mini-modules with a 2D/3D heterojunction architecture ...

Machine learning helps identify six promising solvents for carbon dioxide electroreduction

Carbon dioxide (CO2) is a primary driver of climate change in Earth's atmosphere. At the State University of New York at ...

Ultrafast X-rays allow researchers to 'watch' how molecules rearrange during a chemical reaction controlled by light

Since the 1980s, researchers have sought to use laser light to control chemical reactions relevant to photochemistry, catalysis and light-responsive materials. But this technique, known as coherent ...

Scientists Discover Hidden Rule That Could Make Fuel Cells Cheaper and More Powerful

A new study reveals that dual-atom catalysts behave in a fundamentally different way than scientists previously thought, challenging a long-standing model used to predict catalytic performance.
BioTechniques

Sequencing by synthesis: the story behind its success and tips for the commercialization of academic ideas

We spoke to David Klenerman, co-developer of sequencing by synthesis, to find out how his work heralded the next generation ...

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company's clinical development portfolio. "We delivered ...